Pharma

Your Article Summary

See Latest Articles

Telavancin for injection (Vibativ): Lipoglycopeptide antibiotic approved for the treatment of complicated skin and skin-structure infections
Formulary , 11/02/09

Telavancin is a lipoglycopeptide antibacterial agent that is a synthetic derivative of vancomycin. This antibiotic inhibits bacterial wall synthesis and disrupts the bacterial membrane barrier function. Telavancin was approved on September 2009, for the treatment of complicated skin and skin–structure infections (cSSSIs) caused by susceptible isolates of the gram–positive microorganisms Staphylococcus aureus (methicillin–susceptible and methicillin–resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, the Streptococcus anginosus group,

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

 See all of Drug/Product Approvals